USFDA13 Apr 2026, 06:41 pm
Indoco Remedies: USFDA Inspection at Aurangabad Facility with Zero 483s
AI Summary
Indoco Remedies Ltd announced that the U.S. Food and Drug Administration (U.S. FDA) completed a Pre-Approval Inspection at the Company's testing facility in Chhatrapati Sambaji Nagar (Aurangabad). The inspection was conducted from April 08, 2026, to April 10, 2026, and concluded with zero Form 483 observations. This positive outcome indicates the facility's compliance with regulatory standards, which is crucial for future product approvals and maintaining market access in the US.
Key Highlights
- USFDA completed Pre-Approval Inspection at Aurangabad facility.
- Inspection took place from April 8 to April 10, 2026.
- Concluded with zero Form 483 observations.
- Positive outcome for regulatory compliance and future approvals.
- Enhances company's standing with US regulatory body.
INDOCOPharmaceuticals
INDOCO REMEDIES LTD.Price Impact